Continuous glucose monitoring (CGM) represents one of the most commercially robust sectors within medical technology, transitioning diabetes management from episodic capillary blood testing to continuous, actionable glycemic trend analysis. Despite widespread adoption among insulin-dependent populations, conventional CGM systems remain tethered to subcutaneous filament architectures that penetrate several millimeters into the skin, introducing tissue trauma, biofouling and ma